Patents Assigned to The Government of the United States of America as represented by the Secretary of the Department of
-
Publication number: 20130315921Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: ApplicationFiled: August 5, 2013Publication date: November 28, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Publication number: 20130302790Abstract: The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus. The invention relates, in part, on the identification of a new strain of HEV genotype 3 virus. Strain Kernow-C1 (genotype 3) of HEV, which was isolated from a chronically infected patient, was used to identify human, pig and deer cell lines permissive for infection. Adaptation of the Kernow-C 1 strain to growth in human hepatoma cells selected for a rare virus recombinant that contained an insertion of 174 ribonucleotides (58 amino acids) of a human ribosomal protein gene and additional mutations.Type: ApplicationFiled: January 10, 2012Publication date: November 14, 2013Applicants: Royal Cornwall Hospital Trust, The Government of the United States of America, as represented by the Secretary, Department of HealtInventors: Suzanne U. Emerson, Priyanka Shukla, Hanh T. Nguyen, Robert H. Purcell, Harry R. Dalton, Richard Bendall
-
Publication number: 20130251631Abstract: Disclosed are oxo-hydroquinazolines that are useful as selective TSHR agonists. The compounds may be used for detecting or treating thyroid cancer, or treating a bone degenerative disorder.Type: ApplicationFiled: May 17, 2013Publication date: September 26, 2013Applicants: Forschungsverbund Berlin E.V., The Government of the United States of America as represented by the Secretary of the Department ofInventors: Marvin C. Gershengorn, Susanne Neumann, Bruce M. Raaka, Craig J. Thomas, James Inglese, Noel T. Southall, Steven Titus, Wei Zheng, Wenwei Huang, Gerd Krause, Gunnar Kleinau
-
Publication number: 20130225954Abstract: A device and methods for treating a subject with dysphagia or other neurological disease, neurological disorder, neurological injury, neurological impairment or neurodegenerative disease that affects voluntary motor control of the hyoid, pharynx, larynx, or oropharyngeal area is disclosed. A device of the invention generally comprises a vibrotactile stimulator for applying at least one stimulus to the outside surface of a subject's neck; a connector for attaching the vibrotactile stimulator to an outside surface of the subject's neck, and a switch control communicatively connected to the vibrotactile stimulator to selectively engage a manual stimulation module and/or automatic stimulation module. Stimulation of an outside surface of the throat area of a subject by a device of the invention stimulates a swallowing reflex in the subject.Type: ApplicationFiled: February 26, 2013Publication date: August 29, 2013Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTInventor: The Government of the United States of America, as represented by the Secretary, Department of Health
-
Publication number: 20130219530Abstract: The present invention provides a method for effectively and reproducibly infecting canines with Leishmania infantum using sand flies to vector the parasite. The inventive method comprises several steps, including ensuring canines are naïve to Leishmania, infecting the canines using bites of Leishmania-infected sand fly bites, and evaluating successful transmission of the Leishmania parasites.Type: ApplicationFiled: March 15, 2013Publication date: August 22, 2013Applicants: The Government Of The United States of America As Represented By The Secretary Of The Department, MERIAL LIMITEDInventors: Laurent Fischer, Shaden Kamahwi, Jesus Valenzuela, Hamide Aslan Suau
-
Publication number: 20130217352Abstract: A miniaturized, ruggedized, field-deployable Portable Exposure Assessment System (PEAS) is used to remotely monitor workers and provide real-time warning of exposure to musculoskeletal injury conditions via alarm and smart-phone transmission. The PEAS unit wirelessly acquires exposure data from sensors; conducts initial data analysis; triggers proximal and remote alarms; sends out text messages with abnormal data, GPS locations, and time stamps to a safety office; and saves data for more extensive assessment. Sensor technology is used in this field-deployable system to simultaneously measure and collect the body loads and awkward postures imposed by package handling as well as driving-related, low-frequency vibration exposures. Wireless technology is used to set up wireless communication links between the sensors and a data logger and between the data logger and a smart phone with GPS, date/time stamp and text messaging capabilities.Type: ApplicationFiled: February 15, 2013Publication date: August 22, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventor: The Government of the United States of America as represented by the Secretary of the Department of
-
Publication number: 20130209506Abstract: The disclosure provides recombinant herpes virus with diminished latency. In embodiments, the recombinant herpes virus comprises a latency gene or transcript linked to an altered or heterologous promoter. The disclosure also provides compositions and methods for inducing immunity in animals using the recombinant herpes viruses.Type: ApplicationFiled: November 9, 2007Publication date: August 15, 2013Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the secretary of the department ofInventors: Jeffrey I. Cohen, Lesley Pesnicak
-
Publication number: 20130202528Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137 (4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptpm (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.Type: ApplicationFiled: April 16, 2013Publication date: August 8, 2013Applicant: The Government of the United States of America as Represented by the Secretary of the Department ofInventor: The Government of the United States of America as Represented by the Secretary of the Departme
-
Publication number: 20130203799Abstract: Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression.Type: ApplicationFiled: April 4, 2013Publication date: August 8, 2013Applicants: The Government of the United States of America as represented by the Secretary of the Department of, The University of North Carolina at Chapel Hill, The Regents of the University of Michigan, Progeria Research Foundation, Inc.Inventors: The Government of the United States of America as represented by the Secretary of the Department, Progeria Research Foundation, Inc., The Regents of the University of Michigan, The University of North Carolina at Chapel Hill
-
Publication number: 20130196936Abstract: The invention relates to compositions and methods for treating kidney and muscle dysfunction that involves use of therapeutic amounts of N-acetyl mannosamine.Type: ApplicationFiled: March 8, 2013Publication date: August 1, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventor: The Government of the United States of America as represented by the Secretary of the Department of Health and
-
Publication number: 20130195893Abstract: Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which includes the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present on the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administered. Compositions containing isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present on the surface of a pathogen of interest are also disclosed. In some examples, the compositions also include isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a.Type: ApplicationFiled: March 27, 2013Publication date: August 1, 2013Applicant: The Government of the United States of America as represented by the Secretary of the department ofInventor: The Government of the United States of America as represented by the Secretary of the Department of He
-
Publication number: 20130178692Abstract: A system and methods for transcranial magnetic stimulation, the system including a helmet, a positioning portion, a stimulator and a cooling system, are disclosed. The helmet includes a coil for deep brain magnetic stimulation. The coil has a base portion, and return portions, which may include a protruding return portion and a contacting return portion. The coil is designed to minimize unintended stimulation of portions of the brain, while reducing accumulation of surface charges. The coil is stimulated at several locations and/or at different times so as to focus the electrical field on a specific deep neuronal structure.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicants: BRAINSWAY, INC., YEDA RESEARCH & DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE, GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTHInventors: BRAINSWAY, INC., GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPART, YEDA RESEARCH & DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE
-
Publication number: 20130177984Abstract: This disclosure provides a novel tumor suppressor, referred to as p28ING5, nucleic acid molecules encoding this protein, and methods of making and using these molecules. Also provided are methods of ameliorating, treating, detecting, prognosing, and diagnosing diseases and conditions associated with abnormal p28ING5 expression, such as neoplasia. Kits are also provided.Type: ApplicationFiled: January 22, 2013Publication date: July 11, 2013Applicant: The Government of the United States of America as Represented by the Secretary of the Department ofInventor: The Government of the United States of America as Represented by the Secretary of the Department of
-
Publication number: 20130149384Abstract: Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus.Type: ApplicationFiled: December 18, 2012Publication date: June 13, 2013Applicant: The Government of the United States of America, as represented by the Secretary, Department of HealtInventor: The Government of the United States of America, as represented by Secretary, Department of Health and Human Servi
-
Publication number: 20130149246Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: November 8, 2012Publication date: June 13, 2013Applicants: Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the United States of America, as represented by the Secretary, Department of HealtInventors: The Government of the United States of America,, Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
-
Publication number: 20130143202Abstract: This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.Type: ApplicationFiled: December 23, 2010Publication date: June 6, 2013Applicant: The Government of the United States of America as represented by the Secretary, Department of HealthInventors: Hana Golding, Surender Khurana
-
Publication number: 20130143772Abstract: Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP's) that occur within the members of the T2R gene family. Some SNP's cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals' sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.Type: ApplicationFiled: November 12, 2012Publication date: June 6, 2013Applicant: The Government of the United States of America as represented by the Secretary of the Department ofInventor: The Government of the United States of America a
-
Patent number: 8427160Abstract: A method of performing high throughput magnetic sensing of one or more samples. The method comprises selecting a first sample having a first bulk magnetic susceptibility, selecting an assay plate having a second bulk magnetic susceptibility matched to the first bulk magnetic susceptibility, the assay plate including multiple wells, introducing the first sample into a plurality of the wells, and performing magnetic sensing on the plurality of wells containing the first sample. Assay plates, caps, kits, and other devices and methods relating to high throughput magnetic sensing are also disclosed.Type: GrantFiled: October 12, 2006Date of Patent: April 23, 2013Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human ServicesInventor: Kenneth W. Fishbein
-
Publication number: 20130095137Abstract: Described herein are recombinant rabies viruses encoding rabies virus glycoprotein and at least one heterologous glycoprotein from another lyssavirus, such as Mokola virus, Lagos bat virus and/or West Caucasian bat virus. In particular embodiments, the recombinant rabies virus includes two or three heterologous lyssavirus glycoproteins. The disclosed recombinant rabies viruses can be used as pan-lyssavirus vaccines to provide protection against lyssaviruses that cause rabies.Type: ApplicationFiled: June 23, 2011Publication date: April 18, 2013Applicant: The Government of the United States of America as Represented by the Secretary of the Department ofInventors: Xianfu Wu, Charles E. Rupprecht, Ivan V. Kuzmin
-
Publication number: 20130085077Abstract: Methods and compositions for the diagnosis, prognosis and/or treatment of prostate associated disorders are disclosed.Type: ApplicationFiled: September 19, 2012Publication date: April 4, 2013Applicants: The Government of the United States of America, as Represented by the Secretary of Department of, THE OHIO STATE UNIVERSITY RESEARCH FOUNDATIONInventors: The Ohio State University Research Foundation, The Government of United States of America, as represented by the Secretary of the Department of Health and Human